

Christopher J Chermansky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2128690/publications.pdf>

Version: 2024-02-01

46
papers

772
citations

516215
16
h-index

525886
27
g-index

46
all docs

46
docs citations

46
times ranked

865
citing authors

#	ARTICLE	IF	CITATIONS
1	Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. <i>Urology</i> , 2004, 63, 780-785.	0.5	107
2	Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. <i>European Urology</i> , 2018, 74, 66-73.	0.9	93
3	Pathophysiology and animal modeling of underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 11-21.	0.6	54
4	A model of intrinsic sphincteric deficiency in the rat: Electrocauterization. <i>Neurourology and Urodynamics</i> , 2004, 23, 166-171.	0.8	52
5	Gaining the patient perspective on pelvic floor disordersâ€™ surgical adverse events. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 185.e1-185.e10.	0.7	46
6	Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder. <i>Journal of Urology</i> , 2017, 197, 982-990.	0.2	36
7	Neurogenic Causes of Detrusor Underactivity. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 325-331.	0.2	29
8	Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. <i>Journal of Urology</i> , 2020, 203, 969-977.	0.2	26
9	Brain-derived neurotrophic factor in urinary continence and incontinence. <i>Nature Reviews Urology</i> , 2014, 11, 579-588.	1.9	24
10	BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F45-F56.	1.3	24
11	Recent advances in imaging and understanding interstitial cystitis. <i>F1000Research</i> , 2018, 7, 1771.	0.8	23
12	Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 521-529.	1.9	22
13	Effect of TRPV4 activation in a rat model of detrusor underactivity induced by bilateral pelvic nerve crush injury. <i>Neurourology and Urodynamics</i> , 2018, 37, 2527-2534.	0.8	21
14	Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder. <i>Journal of Urology</i> , 2017, 198, 897-904.	0.2	19
15	Electrical Stimulation of Somatic Afferent Nerves in the Foot Increases Bladder Capacity in Healthy Human Subjects. <i>Journal of Urology</i> , 2014, 191, 1009-1013.	0.2	17
16	Role of pelvic floor in lower urinary tract function. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2016, 200, 43-48.	1.4	17
17	Advanced therapeutic directions to treat the underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 35-44.	0.6	16
18	Use of Botulinum Toxin in Urologic Diseases. <i>Urology</i> , 2016, 91, 21-32.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Biomarkers for Interstitial Cystitis/Painful Bladder Syndrome. <i>Women's Health</i> , 2016, 12, 87-90.	0.7	12
20	Future Perspectives in Bladder Tissue Engineering. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 443-448.	0.2	11
21	Transcutaneous Electrical Nerve Stimulation of the Foot: Results of a Novel At-home, Noninvasive Treatment for Nocturnal Enuresis in Children. <i>Urology</i> , 2017, 101, 80-84.	0.5	11
22	Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond. <i>International Urology and Nephrology</i> , 2018, 50, 401-409.	0.6	11
23	Sacral Neuromodulation: Determining Predictors of Success. <i>Urology</i> , 2021, 153, 124-128.	0.5	11
24	MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxinA injection. <i>Neurourology and Urodynamics</i> , 2018, 37, 99-105.	0.8	8
25	How can we improve the diagnosis and management of bladder pain syndrome? Part 2: ICIâ€RS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S71-S81.	0.8	8
26	How can we better manage drugâ€resistant OAB/DO? ICIâ€RS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S46-S55.	0.8	6
27	Excitatory effect of acotiamide on rat and human bladder: Implications for underactive bladder treatment. <i>Life Sciences</i> , 2020, 258, 118179.	2.0	5
28	Virtual measurements of paracellular permeability and chronic inflammation via color coded pixel-wise T1 mapping. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, F506-F514.	1.3	5
29	Low pressure voiding induced by stimulation and 1ÂkHz post-stimulation block of the pudendal nerves in cats. <i>Experimental Neurology</i> , 2021, 346, 113860.	2.0	5
30	Using the Native Afferent Nervous System to Sense Bladder Fullness: State of the Art. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 346-349.	0.2	4
31	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICIâ€RS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S66-S70.	0.8	4
32	Stem cells and lower urinary tract dysfunction: Has its potential finally reached clinical maturity? ICIâ€RS2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S134-S141.	0.8	4
33	Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence. <i>Journal of Urology</i> , 2022, 208, 855-862.	0.2	4
34	Cost-effectiveness of behavioral and pelvic floor muscle therapy combined with midurethral sling surgery vs surgery alone among women with mixed urinary incontinence: results of the Effects of Surgical Treatment Enhanced With Exercise for Mixed Urinary Incontinence randomized trial. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 651.e1-651.e26.	0.7	3
35	Functional and histologic imaging of urinary bladder wall after exposure to psychological stress and protamine sulfate. <i>Scientific Reports</i> , 2021, 11, 19440.	1.6	3
36	Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome. <i>Urologic Clinics of North America</i> , 2022, 49, 273-282.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Are there relevant animal models to set research priorities in LUTD? ICIâ€RS 2019. Neurourology and Urodynamics, 2020, 39, S9-S15.	0.8	2
38	Urethral dysfunction and therapeutic effects of a PDE 5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury. Neurourology and Urodynamics, 2020, 39, 916-925.	0.8	2
39	Constitutively active HCN channels constrain detrusor excitability and modulate evoked contractions of human bladder. American Journal of Clinical and Experimental Urology, 2020, 8, 163-176.	0.4	2
40	Defecation Induced by Stimulation of Sacral S2 Spinal Root in Cats. American Journal of Physiology - Renal Physiology, 2021, , .	1.6	2
41	Role of hyperpolarization-activated cyclic nucleotide-gated channels in aging bladder phenotype. Life Sciences, 2022, 289, 120203.	2.0	2
42	Deciding Our Future: Consensus Conference Summary Report. Female Pelvic Medicine and Reconstructive Surgery, 2020, 26, 159-161.	0.6	1
43	Underactive Bladder and Bladder Outlet Procedures in Women. Current Bladder Dysfunction Reports, 2020, 15, 21-24.	0.2	1
44	Recent Developments in Imaging in BPS/IC. Current Bladder Dysfunction Reports, 2019, 14, 301-307.	0.2	0
45	Do we have adequate data to construct a valid algorithm for management of synthetic midurethral sling complications? ICIâ€RS 2019. Neurourology and Urodynamics, 2020, 39, S122-S131.	0.8	0
46	Reply by Authors. Journal of Urology, 2020, 203, 977-977.	0.2	0